AGNG

Aging Population ETF

Morningstar Rating™ - Overall rating out of 165 Health funds, based on risk-adjusted returns as of 01/31/2025

Reasons to Consider AGNG

Long-Term Growth Potential

Humans are living longer than ever, with forecasts suggesting the global population of adults age 60+ could double to more than 2bn by 2050.¹

Demographics Drive Consumption

With a ballooning senior population, particularly in western countries, we expect to see waves of innovation catering to seniors' distinct consumer preferences.

Unconstrained Approach

The Aging Population theme is a global trend, affecting a wide range of industries. AGNG invests accordingly, offering exposure to companies regardless of sector or geographic classification.

¹WHO, Oct 2022

Key Information As of 02/12/25

Inception Date	05/09/16
Total Expense Ratio	0.50%
Net Assets	$60.41 million
NAV	$31.63
Fact Sheet	View the document

ETF Summary

The Global X Aging Population ETF (AGNG) seeks to invest in companies positioned to serve the world’s growing senior population through exposure to health care, pharmaceuticals, senior living facilities and other sectors that contribute to increasing lifespans and extending quality of life in advanced age.

ETF Objective

The Global X Aging Population ETF (AGNG) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Indxx Aging Population Thematic Index.

Trading Details As of 02/12/25

Ticker	AGNG
Bloomberg Index Ticker	ILNGRNT
CUSIP	37954Y772
ISIN	US37954Y7720
Primary Exchange	Nasdaq
Shares Outstanding	1,910,000
Number of Holdings	83
30-Day Median Bid-Ask Spread	0.35%

Distributions As of 02/12/25

30-Day SEC Yield	0.95%
Distribution Frequency	Semi-Annually

ETF Prices As of 02/12/25

NAV	$31.63	Daily Change	$0.04	0.13%
Market Price	$31.60	Daily Change	$0.05	0.16%

As of recent (12/31/24) As of recent (12/31/24)	Fund NAV	Market Price	Index
1 Year	6.81%	7.04%	7.21%
3 Years	2.34%	2.36%	2.65%
5 Years	5.79%	5.80%	6.07%
Since Inception	9.08%	9.34%	9.39%
1 Year	13.18%	12.71%	13.56%
3 Years	6.95%	6.63%	7.27%
5 Years	7.12%	6.90%	7.41%
Since Inception	9.65%	9.82%	9.95%
Year-to-Date	6.81%	7.04%	7.21%
1 Month	-4.90%	-5.05%	-4.86%
3 Months	-7.34%	-7.59%	-7.21%
Since Inception	112.18%	116.59%	117.32%
Year-to-Date	5.36%	4.67%	5.39%
1 Month	5.36%	4.67%	5.39%
3 Months	-0.05%	-0.80%	0.06%
Since Inception	123.57%	126.71%	129.03%

Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.

Net Assets (%)	Ticker	Name	SEDOL	Market Price ($)	Shares Held	Market Value ($)
4.50	WELL	WELLTOWER INC	BYVYHH4	146.50	18,564	2,719,626.00
4.27	BSX	BOSTON SCIENTIFIC CORP	2113434	105.77	24,369	2,577,509.13
3.67	4519 JP	CHUGAI PHARMA CO	6196408	45.16	49,075	2,216,310.82
3.23	UCB BB	UCB SA	5596991	197.46	9,878	1,950,515.36
3.20	ABBV	ABBVIE INC	B92SR70	193.00	10,013	1,932,509.00
3.19	LLY	ELI LILLY & CO	2516152	872.97	2,208	1,927,517.76
3.17	BMY	BRISTOL-MYERS SQUIBB CO	2126335	56.15	34,150	1,917,522.50
3.09	SYK	STRYKER CORP	2853688	385.63	4,844	1,867,991.72
3.09	MDT	MEDTRONIC PLC	BTN1Y11	91.35	20,412	1,864,636.20
3.05	RO SW	ROCHE HOLDING AG-BR	7108918	341.12	5,400	1,842,071.27
3.03	AMGN	AMGEN INC	2023607	295.06	6,212	1,832,912.72
2.99	ALC SW	ALCON INC	BJT1GR5	88.50	20,430	1,808,047.73
2.98	AZN	ASTRAZENECA PLC-SPONS ADR	2989044	74.43	24,151	1,797,558.93
2.90	JNJ	JOHNSON & JOHNSON	2475833	155.26	11,273	1,750,245.98
2.35	068270 KS	CELLTRION INC	B0C5YV1	122.95	11,554	1,420,538.36
2.30	EW	EDWARDS LIFESCIENCES CORP	2567116	75.82	18,347	1,391,069.54
2.27	4543 JP	TERUMO CORP	6885074	18.08	75,699	1,368,703.79
2.02	VTR	VENTAS INC	2927925	59.94	20,387	1,221,996.78
2.00	REGN	REGENERON PHARMACEUTICALS	2730190	663.86	1,822	1,209,552.92
1.81	NOVOB DC	NOVO NORDISK A/S-B	BP6KMJ1	81.46	13,440	1,094,796.81
1.79	ONC	BEIGENE LTD-ADR	BYYWPW6	223.31	4,843	1,081,490.33
1.78	STMN SW	STRAUMANN HOLDING AG-REG	BQ7ZV06	133.50	8,068	1,077,117.08
1.77	SDZ SW	SANDOZ GROUP AG	BLPLD38	49.04	21,826	1,070,452.46
1.70	ZBH	ZIMMER BIOMET HO	2783815	98.99	10,388	1,028,308.12
1.67	DXCM	DEXCOM INC	B0796X4	83.87	12,008	1,007,110.96
1.65	SOON SW	SONOVA HOLDING AG-REG	7156036	331.27	3,017	999,446.28
1.64	PODD	INSULET CORP	B1XGNW4	279.55	3,546	991,284.30
1.46	UTHR	UNITED THERAPEUTICS CORP	2430412	370.74	2,383	883,473.42
1.43	4503 JP	ASTELLAS PHARMA INC	6985383	9.38	91,841	861,353.16
1.30	INCY	INCYTE CORP	2471950	69.05	11,368	784,960.40
1.26	DVA	DAVITA INC	2898087	172.00	4,440	763,680.00
1.20	FME GR	FRESENIUS MEDICAL CARE AG	5129074	48.53	14,924	724,224.03
1.10	3692 HK	HANSOH PHARMACEU	BJYKB72	2.22	299,843	665,830.27
1.06	GMAB DC	GENMAB A/S	4595739	190.95	3,354	640,460.91
1.06	COH AU	COCHLEAR LTD	6211798	192.43	3,318	638,492.50
0.98	NBIX	NEUROCRINE BIOSC	2623911	117.18	5,037	590,235.66
0.93	SN/ LN	SMITH & NEPHEW PLC	0922320	12.68	44,472	563,703.10
0.92	PHM SM	PHARMA MAR SA	BMW2GT8	98.50	5,656	557,098.31
0.83	EXEL	EXELIXIS INC	2576941	32.80	15,340	503,152.00
0.77	EXAS	EXACT SCIENCES CORP	2719951	50.34	9,185	462,372.90
0.73	OHI	OMEGA HEALTHCARE	2043274	35.72	12,409	443,249.48
0.68	DEMANT DC	DEMANT A/S	BZ01RF1	35.91	11,356	407,793.83
0.67	TFX	TELEFLEX INC	2881407	168.33	2,387	401,803.71
0.62	HALO	HALOZYME THERAPEUTICS INC	2975098	58.11	6,433	373,821.63
0.60	ENSG	ENSIGN GROUP INC/THE	B1YWPP8	126.12	2,867	361,586.04
0.60	GKOS	GLAUKOS CORP	BYMWL19	143.64	2,504	359,674.56
0.53	BPMC	BLUEPRINT MEDICINES CORP	BWY52P3	103.56	3,101	321,139.56
0.52	MMSI	MERIT MEDICAL SYSTEMS INC	2580555	107.76	2,936	316,383.36
0.52	AMP IM	AMPLIFON SPA	B14NJ71	27.50	11,480	315,703.27
0.47	YPSN SW	YPSOMED HOLDING AG-REG	B02SWN8	409.98	691	283,299.03
0.42	NVCR	NOVOCURE LTD	BYSS4X4	21.37	11,862	253,490.94
0.42	EMBC	EMBECTA CORP	BMXWYR1	16.62	15,216	252,889.92
0.39	ITGR	INTEGER HOLDINGS CORP	BD06LM7	137.34	1,694	232,653.96
0.36	MNKD	MANNKIND CORP	BF081J4	5.60	38,960	218,176.00
0.34	CSH-U CN	CHARTWELL RETIRE	B8S8C94	11.27	18,273	205,923.56
0.34	853 HK	MICROPORT SCIENTIFIC CORP	B676TW7	0.95	216,302	204,899.27
0.32	SBRA	SABRA HEALTH CAR	B5NLBP6	16.10	12,152	195,647.20
0.31	SIA CN	SIENNA SENIOR LIVING INC	BWTYXH4	10.98	17,266	189,623.45
0.31	NHI	NATL HEALTH INVESTORS INC	2626125	65.79	2,844	187,106.76
0.31	NHC	NATIONAL HEALTHCARE CORP	2139731	100.20	1,865	186,873.00
0.30	ACAD	ACADIA PHARMACEU	2713317	19.10	9,623	183,799.30
0.30	DNLI	DENALI THERAPEUTICS INC	BD2B4V0	20.82	8,742	182,008.44
0.30	AGIO	AGIOS PHARMACEUTICALS INC	BCBVTX1	32.81	5,472	179,536.32
0.29	8086 JP	NIPRO CORP	6641599	8.73	20,328	177,554.94
0.29	LTC	LTC PROPERTIES INC	2498788	33.72	5,206	175,546.32
0.29	TBPH	THERAVANCE BIOPHARMA INC	BMNDK09	9.36	18,741	175,415.76
0.28	AMED	AMEDISYS INC	2024332	92.66	1,814	168,085.24
0.28	AED BB	AEDIFICA	B1G5XP1	61.67	2,689	165,832.68
0.26	1789 HK	AK MEDICAL HOLDINGS LTD	BFD6SZ0	0.65	244,489	158,166.09
0.25	RYM NZ	RYMAN HEALTHCARE LTD	6161525	2.42	62,200	150,619.75
0.25	GN DC	GN STORE NORD A/S	4501093	19.66	7,651	150,408.73
0.24	LIVN	LIVANOVA PLC	BYMT0J1	47.65	3,096	147,524.40
0.23	EKTAB SS	ELEKTA AB-B SHS	B0M42T2	6.01	22,913	137,657.62
0.22	1302 HK	LIFETECH SCIENTIFIC CORP	BV9FKS0	0.18	734,692	134,854.32
0.21	2186 HK	LUYE PHARMA GROUP LTD	BNQ4GF3	0.28	465,424	129,040.50
0.21	ATEC	ALPHATEC HOLDINGS INC	BD60BG7	10.68	11,947	127,593.96
0.21	BKD	BROOKDALE SR	B0PZN33	4.93	25,134	123,910.62
0.19	AGL	AGILON HEALTH INC	BLR4TK4	3.57	31,426	112,190.82
0.18		OTHER PAYABLE & RECEIVABLES		1.00	106,411	106,411.15
0.15	145720 KS	DENTIUM CO LTD	BF07GJ6	49.40	1,774	87,638.09
0.07	2500 HK	VENUS MEDTECH -H	BL6V047	0.43	102,940	44,554.88
0.07	ALEC	ALECTOR INC	BJ4LDC4	1.64	26,820	43,984.80
0.05	9229 JP	SUNWELS CO LTD	BNTYNB5	3.08	10,514	32,336.11
0.00		RADIUS HEALTH INC - CVR	2KFF9T0	0.00	19,104	0.02
0.00		DANISH KRONE		0.14	-308	-42.84
-0.01		CASH		1.00	-2,766	-2,765.81

Holdings are subject to change. "Cash" denotes U.S. dollars.

Exposure As of 01/31/25

	Sector	Weight (%)
	Health Care	91.8
	Real Estate	8.2

Source: new windowAltaVista Research, LLC

	Industry	Weight (%)
	Pharmaceuticals, Biotechnology & Life Sciences	46.2
	Health Care Equipment & Services	41.1
	Equity Real Estate Investment Trusts (REITs)	8.2
	Pharmaceuticals, Biotechnology	4.5

Source: new windowAltaVista Research, LLC

	Country	Weight (%)
	United States	53.8
	Switzerland	11.9
	Japan	7.7
	Britain	4.5
	Denmark	4.0
	China	3.9
	Belgium	3.5
	Ireland	3.1
	South Korea	2.5
	Germany	1.2
	Australia	1.1
	Other	2.8

Source: new windowAltaVista Research, LLC

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.

ETF Characteristics As of 02/12/25

Return on Equity	16.30%
Weighted Avg. Market Cap	99,300 M
	2024	2025
Price-to-earnings	27.25	20.48
Price-to-book value	3.53	3.17

Source: new windowAltaVista Research, LLC

ETF Risk Stats As of 01/31/25

Versus	Beta
S&P 500	0.69
NASDAQ-100	0.46
MSCI EAFE	0.73
MSCI Emg. Mkts	0.49
Standard Deviation	15.00%

Source: new windowAltaVista Research, LLC

ETF Research

ETF Documents

Latest Premium / Discount As of 02/12/25

NAV	$31.63
Market Price	$31.60
Premium / (Discount)	($0.03)

Current View 2025 Q1 As of 02/12/25

Days at Premium	10
Days at NAV	0
Days at Discount	18
Greatest Premium	0.23%
Greatest Discount	-0.69%

Daily Premium / Discount History As of 02/12/25

Hover over the chart points for details

View Chart Explanation

Download Chart Data (.CSV)

How can the Fund trade at a premium/discount to its NAV?

The primary explanation is that timing discrepancies can arise between the NAV and the trading price of the Fund. Since shares of the Fund trade on the open market, prices are affected by the constant flow of information received by investors, corporations and financial institutions. Depending on how this changing information affects investor sentiment, shares of the Fund may deviate slightly from the value of the Fund's underlying assets. The NAV of the Fund is only calculated once a day (normally at 4:00 p.m. eastern time). As a result, shareholders may pay more than NAV when they buy Fund shares and receive less than NAV when they sell those shares, because shares are purchased and sold at current market prices. However, due to the creation and redemption process that is unique to ETFs, market makers are able to minimize these deviations from NAV by taking advantage of arbitrage opportunities.

What causes these time discrepancies?

Close of Trading Times. Although both the NAV and the daily market price of the Fund are generally calculated based on prices at the closing time of the exchange (generally 4:00 p.m. eastern time), slight differences in this timing may cause discrepancies.

Time of Last Trade. Trading of Global X funds generally takes place during normal trading hours (9:30 a.m. to 4:00 p.m. eastern time). However, it is important to note that the last trade - from which the closing price is determined - may not occur at exactly 4:00 p.m. eastern time. Therefore, changing market sentiment during the time difference may cause the NAV to deviate from the closing price.

International Holdings. The premiums and discounts for funds with significant holdings in international markets may be less accurate due to the different closing times of various international markets. Because the Funds trade during U.S. market hours while the underlying securities may not, the time lapse between the markets can result in differences between the NAV and the trading price.

The Morningstar Rating™ for funds, or “star rating”, is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The Morningstar Rating does not include any adjustment for sales load. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three- year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.

As of 1/31, AGNG was rated against the following numbers of Health funds over the following time periods: 165 during the last 3 years, 149 during the last 5 years. With respect to these Technology funds, AGNG received a Morningstar Rating of 5, and 3 stars, respectively. Past performance is not indicative of future results.

© 2025 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Investing involves risk, including the possible loss of principal. The investable universe of companies in which AGNG may invest may be limited. The Fund invests in securities of companies engaged in Healthcare, Pharmaceutical, Biotechnology and Medical Device sectors. These sectors can be affected by government regulations, expiring patents, rapid product obsolescence, and intense industry competition. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Indxx, nor does Indxx make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Indxx.

AGNG traded under the ticker LNGR from inception until April 1, 2021.

AGNG

Aging Population ETF

Morningstar Rating™ - Overall rating out of 165 Health funds, based on risk-adjusted returns as of 01/31/2025

Reasons to Consider AGNG

Long-Term Growth Potential

Demographics Drive Consumption

Unconstrained Approach

Key Information As of 02/12/25

ETF Summary

ETF Objective

Trading Details As of 02/12/25

Distributions As of 02/12/25

ETF Prices As of 02/12/25

Performance History

Top Holdings As of 02/12/25

Exposure As of 01/31/25

ETF Characteristics As of 02/12/25

ETF Risk Stats As of 01/31/25

ETF Research

Investing in Pharma: How to Spot Leading Drug Candidates

Investing in Pharma: The Drug Lifecycle

In the Pipeline: Top Drug Candidates for FDA Approval in 2024

ETF Documents